Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + selinexor + CHOP
- Development stage
- Unknown
- Lead developer
- Karyopharm Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Decitabine + selinexor + CHOP is an investigational combination regimen being evaluated for the treatment of newly diagnosed peripheral T-cell lymphoma (PTCL). The regimen incorporates two targeted agents into the standard CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). **Decitabine** is a DNA methyltransferase (DNMT) inhibitor that acts as an epigenetic modulator, while **selinexor** is a selective inhibitor of nuclear export (SINE) that targets Exportin-1 (XPO1). This combination is part of a genotype-guided therapeutic strategy, specifically investigated by Ruijin Hospital in the GUIDANCE-03 trial (NCT04480099), where it is matched to patients with specific genomic profiles, such as those with TP53 mutations.
- Other names
- Decitabine plus Selinexor with CHOPCHOPX2CHOPX-2CHOPX 2
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)TUBB (Tubulin (alpha and beta subunits))XPO1 (Exportin-1)
Beyond the preview
Go deeper on decitabine + selinexor + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + selinexor + CHOP.